Dear Urea Cycle Disorders Consortium research participants, First, I would like to thank you for your participation in urea cycle disorders (UCD) research. With your help we have been able to conduct observational studies and clinical trials that have added to our knowledge of UCDs and how to treat them. The research has led to changes in treatment guidelines and has helped us secure a second cycle of NIH funding.
We are very excited about what we have learned from these important studies so far and look forward to continuing our work with you to keep learning about UCD. Our goal is to improve the outcome of all individuals with UCDs and to spread knowledge about these disorders so physicians can treat them more rapidly and effectively. We thank you for your help in making this possible.
Mark Batshaw, MD Director, Urea Cycle Disorders Consortium
Greetings from the UCDC Leadership The Urea Cycle Disorders Consortium (UCDC) was created as part of a larger network established by the National Institutes of Health to study rare diseases. This paper reviews the UCDC's accomplishments over the first six years, including how the Consortium was developed and organized, clinical research studies initiated, and the importance of creating partnerships with patient advocacy groups, philanthropic foundations and biotech and pharmaceutical companies. On behalf of all of the National Urea Cycle Disorders Foundation and our UCD patients and families around the world, I would like to thank you for your contribution to moving UCD research forward! Your participation in the Longitudinal Study and other important UCD studies has increased the understanding of UCDs and made it possible for researchers to delve deeper into the many questions we have had for so long about UCDs and the effects on our UCD children and adults. By standing together as a UCD community focused on research progress, you have helped to catalyze the development of new interventions and therapies to improve the lives of patients with UCD.
Cross-Sectional
We are so pleased to be able to report the findings of the UCDC studies to you --accomplishments you helped make possible in a relatively short time. We need to learn much, much more about the mysteries of UCDs. The new research projects will help unlock these mysteries, and your continued participation will be the key.
We look forward to keeping you posted about the progress of the studies. (first Longitudinal Study visit) . This first report resulting from the Longitudinal Study describes the patient population. Onehundred eighty three participants were enrolled into the study at the time this report was written. Ornithine transcarbamylase deficiency (OTCD) was the most frequent disorder (55% of total enrolled), followed by argininosuccinic aciduria (ASA) (16%) and citrullinemia (14%). Seventy-nine percent of the participants were white, 7% were Asian, 5% were African American, and 9% did not give their race or reported more than one race. Sixteen percent of participants were Latino. Intellectual and developmental disabilities were reported by 39% of participants, learning disabilities were reported by 35%, and half had abnormal neurological examinations (including findings like tone changes, reflex abnormalities, and abnormal movements). Sixty-three percent were on a protein restricted diet, 37% were on sodium phenylbutyrate (Buphenyl) and 5% were on sodium benzoate. Forty-five percent of OTCD participants were on L-citrulline. Most participants with citrullinemia (58%) and argininosuccinic aciduria (79%) were on L-arginine. Plasma levels of branched-chain amino acids (valine, leucine and isoleucine) were reduced in patients treated with ammonia scavenger drugs (sodium phenylbutyrate and sodium benzoate). Plasma glutamine levels were higher in proximal UCD (OTCD and carbamyl phosphates synthetase I deficiency -CPSID) and in neonatal type disease. Urea cycle disorders can lead to an accumulation of ammonia in the blood and brain and result in neurodevelopmental disabilities. This analysis of data from the Longitudinal Study of Urea Cycle Disorders was to describe the intellectual, adaptive, and emotional/ behavioral functioning of children with Urea Cycle Disorders (UCDs). Intellectual functioning refers to a person's ability to learn, think, solve problems, and make sense of the world. Adaptive behavior includes the age-appropriate behaviors necessary for people to live independently and to function safely and appropriately in daily life. Adaptive behaviors include real life skills such as grooming, dressing, safety, safe food handling, school rules, ability to work, money management, cleaning, making friends, social skills, and personal responsibility expected based on age. Emotional/behavioral functioning measures assess one's ability to learn, build and maintain interpersonal relationships, behavior, feelings, mood, and fears.
These domains were measured through testing and parent questionnaires in 92 children with UCDs (33 neonatal onset, 59 late onset). Results show that children who present with UCD later in childhood have better outcomes than those who present with neonatal onset UCD (symptoms in the first month of life). Approximately half of the children with neonatal onset UCD performed in the range of intellectual disability (ID), including about 30% who were severely impaired. In comparison, only a quarter of the late onset group were in the range of ID. There is also evidence that those with UCD have difficulties with some emotional/behavioral and executive function skills (difficulties with behavior regulation, organization, and goal directed behaviors). In conclusion, children with UCDs present with a wide spectrum of intellectual and behavioral outcomes. Children with neonatal onset UCDs have a much higher likelihood of having an intellectual disability, which becomes more evident with increasing age. However, even children with late onset UCDs demonstrate evidence of neurocognitive (intellectual) and behavioral impairment, particularly in aspects of attention and executive functioning (intellectual processes). Enzyme defects of the urea cycle typically present with significant hyperammonemia (high ammonia levels) in the first few months of life. However, arginase I (ARG1) deficiency has classically been the exception. ARG1 deficiency usually presents later in life with spasticity, seizures, failure to thrive, and developmental regression. Neonatal and early presentation as an infant with severe hyperammonemia remains rare and only six such cases have been described. We report a severely affected infant with ARG1 deficiency who presented at six weeks of age with lethargy, poor feeding and severe encephalopathy (abnormal brain function) caused by high ammonia levels. This paper reviews the clinical and biochemical features of this infant and six other previously reported cases of neonatal or early presentation ARG1 deficiency. In addition, this paper presents the clinical spectrum of seven previously unpublished patients with later onset ARG1deficiency, who also experienced recurrent hyperammonemia. Several biochemical abnormalities have been thought to play a role in the neurological changes in ARG1 deficiency including high arginine levels, elevated guanidino compounds and elevated glutamine levels, as well as the high ammonia levels. Our case demonstrated many of these. The cases reviewed suggest a correlation between genotype (inherited information) and phenotype (actual observed properties) and provide support for the addition of arginine as a primary target in newborn screening programs.
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Despite the success of childhood immunizations in prevention of infectious diseases, questions remain about the safety of vaccines in medically fragile children with inborn errors of metabolism such as urea cycle disorders (UCDs). Patients with UCDs are subject to hyperammonemic episodes (HAEs) (episodes of elevated ammonia levels) after infection, fever, or other stressors. We sought to assess the risk of HAEs that required urgent care or hospitalization after routine vaccinations in pediatric patients with underlying UCDs. This was an investigation of vaccine safety in children with UCDs from data collected from the Longitudinal Study of Urea Cycle Disorders. Post-vaccination exposure periods were defined as 7 or 21 days after any immunization. The study included 169 children younger than 18 years. Of these children, 74 had records of at least 1 HAE and at least 1 vaccination. With adjustment for age, there was no increase in relative incidence of HAEs in either the 7-day or 21-day exposure period after vaccination compared with HAEs outside of the vaccination periods. No vaccine type was associated with significantly more HAEs. We found no statistically significant association between childhood immunizations and HAEs in children with UCDs. The results support the safety of immunization in this medically vulnerable population. A 66 year old woman with symptomatic ornithine transcarbamylase deficiency (OTCD) presented with hepatocellular carcinoma (HCC) (liver cancer). Fourteen years before being diagnosed with HCC she participated in a phase I gene therapy study which used an adenoviral vector to deliver a normal OTC gene to hepatocytes. The vector used is not thought to cause cancer. A recent review of data collected by the Longitudinal Study of Urea Cycle Disorders found three additional patients being treated for HCC which is higher than would be anticipated in this population. This suggests that those with urea cycle disorders (UCDs) may be at increased risk of developing liver cancer as has been observed in certain other inborn errors of metabolism. We will be studying this further to determine if there is, in fact, an increased risk of liver cancer in urea cycle disorders that could be related to chronic liver inflammation. If this is found to be the case, we might recommend annual abdominal ultrasounds for early detection of liver cancer as is recommended for other disorders that have an increased risk of liver cancer. At this point it is too soon to make these recommendations or establish guidelines, as additional studies are needed. It is thought that these complications may be due, in part, to accumulation of argininosuccinic acid upstream of the metabolic block or deficiency of arginine downstream of the block. In order to test this hypothesis, we conducted this trial comparing high-dose arginine alone with low-dose arginine with sodium phenylbutyrate in 12 patients with ASA. Results will be reported in our next issue of the UCDC Update Newsletter.
Vaccines Are Not Associated With Metabolic Events in Children With

Hepatocellular Carcinoma in a Research
Assessing Neural Mechanisms of Injury in Inborn Errors of Urea Metabolism Using
Structural MRI, Functional MRI, and Magnetic Resonance Spectroscopy: This neuroimaging study using structural magnetic resonance imaging, functional magnetic resonance imaging, and magnetic resonance spectroscopy is complete. Another project has grown out of this study and uses a neuroimaging scheme to evaluate a series of brain biomarkers and their association with neural injury and recovery in a group of urea cycle disorders (see the neuroimaging study described below). Several publications have been published, one of which is summarized on page 7. Other findings will be focused on in of our next UCDC Update Newsletter
Open for Enrollment
N-carbamylglutamate in the Treatment of Hyperammonemia: N-carbamylglutamate is a chemical compound with a similar structure to N-acetylglutamate, which is essential to the first step of the urea cycle. In this study, we investigate the effect of N-carbamylglutamate (NCG, Carbaglu®) on ureagenesis (metabolism of amino acids to urea) in patients with any of four inborn errors of metabolism that cause hyperammonemia including: carbamyl phosphate synthetase I (CPSI) deficiency, ornithine transcarbamylase (OTC) deficiency, propionic acidemia (PA) and methylmalonic acidemia (MMA). One of the articles resulting from this study is summarized on page 6.
The Carbaglu Surveillance Protocol: The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. 
